Arrowhead Pharmaceuticals Management
Management Kriterienprüfungen 3/4
Arrowhead Pharmaceuticals' CEO ist Chris Anzalone , ernannt in Dec 2007, hat eine Amtszeit von 16.67 Jahren. Die jährliche Gesamtvergütung beträgt $9.92M , bestehend aus 9.1% Gehalt und 90.9% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 2.99% der Aktien des Unternehmens, im Wert von $84.18M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 6.1 Jahre bzw. 13.8 Jahre.
Wichtige Informationen
Chris Anzalone
Geschäftsführender
US$9.9m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 9.1% |
| Amtszeit als Geschäftsführer | 16.8yrs |
| Eigentum des Geschäftsführers | 3.0% |
| Durchschnittliche Amtszeit des Managements | 6.2yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 13.8yrs |
Jüngste Management Updates
Recent updates
Arrowhead Pharmaceutical: Driving To Commercialization
Jul 26Estimating The Fair Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Jun 12
Arrowhead Pharmaceuticals: Hoping Something Sticks
May 27Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?
May 21Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point
May 17Some Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shareholders Look For Exit As Shares Take 27% Pounding
Apr 03Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade)
Mar 30Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package
Mar 08Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Feb 19Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy
Jan 21Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now
Dec 25Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?
Sep 19Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up
Apr 17Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now
Mar 10A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Jan 24We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn
Oct 24Arrowhead Pharmaceuticals: Emerging From The 'Data Desert' With A Flood Of Opportunities
Sep 12Johnson & Johnson And Arrowhead Pharmaceuticals Could Have Big News Coming
Aug 23Arrowhead seeks New Zealand regulator nod to start trial of ARO-MMP7 for lung disease
Aug 17Arrowhead Pharmaceuticals: An RNAi Name To Know
Jul 28Arrowhead Pharmaceuticals names internal officer as new COO
Jul 20Arrowhead begins dosing in early-stage studies of 2 potential lung disease drugs
Jul 05Arrowhead Pharma: We Can Afford To Wait For More Proof
Jun 28Companies Like Arrowhead Pharmaceuticals (NASDAQ:ARWR) Can Afford To Invest In Growth
Jun 18Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$539m |
| Mar 31 2024 | n/a | n/a | -US$471m |
| Dec 31 2023 | n/a | n/a | -US$297m |
| Sep 30 2023 | US$10m | US$903k | -US$205m |
| Jun 30 2023 | n/a | n/a | -US$181m |
| Mar 31 2023 | n/a | n/a | -US$150m |
| Dec 31 2022 | n/a | n/a | -US$155m |
| Sep 30 2022 | US$12m | US$863k | -US$176m |
| Jun 30 2022 | n/a | n/a | -US$154m |
| Mar 31 2022 | n/a | n/a | -US$112m |
| Dec 31 2021 | n/a | n/a | -US$183m |
| Sep 30 2021 | US$25m | US$837k | -US$141m |
| Jun 30 2021 | n/a | n/a | -US$126m |
| Mar 31 2021 | n/a | n/a | -US$110m |
| Dec 31 2020 | n/a | n/a | -US$103m |
| Sep 30 2020 | US$14m | US$786k | -US$85m |
| Jun 30 2020 | n/a | n/a | -US$24m |
| Mar 31 2020 | n/a | n/a | US$10m |
| Dec 31 2019 | n/a | n/a | US$53m |
| Sep 30 2019 | US$2m | US$674k | US$68m |
| Jun 30 2019 | n/a | n/a | US$46m |
| Mar 31 2019 | n/a | n/a | US$10m |
| Dec 31 2018 | n/a | n/a | -US$29m |
| Sep 30 2018 | US$2m | US$643k | -US$54m |
| Jun 30 2018 | n/a | n/a | -US$54m |
| Mar 31 2018 | n/a | n/a | -US$44m |
| Dec 31 2017 | n/a | n/a | -US$35m |
| Sep 30 2017 | US$2m | US$616k | -US$34m |
Vergütung im Vergleich zum Markt: ChrisDie Gesamtvergütung ($USD9.92M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD6.84M).
Entschädigung vs. Einkommen: ChrisDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.
Geschäftsführer
Chris Anzalone (55 yo)
16.8yrs
Amtszeit
US$9,918,093
Vergütung
Dr. Christopher R. Anzalone, also known as Chris, Ph D., has been the Chief Executive Officer and President at Arrowhead Pharmaceuticals, Inc. since December 1, 2007. He serves as Chief Executive Officer o...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO, President & Director | 16.8yrs | US$9.92m | 2.99% $ 72.9m | |
| Chief Financial Officer | 14.6yrs | US$3.12m | 0.19% $ 4.6m | |
| COO, General Counsel & Secretary | 9.8yrs | US$3.31m | 0.23% $ 5.6m | |
| Chief of Discovery & Translational Medicine | no data | US$3.05m | 0.16% $ 4.0m | |
| Founder and Founder & Director of Insert Therapeutics Inc & Calando | no data | keine Daten | keine Daten | |
| Head of Investor Relations & VP | no data | keine Daten | keine Daten | |
| Director of Communications | 19.1yrs | keine Daten | keine Daten | |
| Chief Medical Scientist | less than a year | US$16.34m | keine Daten | |
| Head of Toxicology & VP | no data | keine Daten | keine Daten | |
| Chief Commercial Officer | 2.3yrs | US$2.97m | 0.013% $ 328.3k | |
| Head of Tax | 2.7yrs | keine Daten | keine Daten | |
| VP & Treasurer | 2.7yrs | keine Daten | keine Daten |
6.2yrs
Durchschnittliche Betriebszugehörigkeit
60yo
Durchschnittliches Alter
Erfahrenes Management: ARWRDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (6.1 ).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO, President & Director | 16.8yrs | US$9.92m | 2.99% $ 72.9m | |
| Founder and Founder & Director of Insert Therapeutics Inc & Calando | no data | keine Daten | keine Daten | |
| Chairman of the Board | 13.8yrs | US$474.60k | 0.11% $ 2.8m | |
| Independent Lead Director | 12.8yrs | US$459.60k | 0.074% $ 1.8m | |
| Independent Director | 6.7yrs | US$469.60k | 0.026% $ 645.1k | |
| Member of Hepatitis B Clinical Advisory Board | no data | keine Daten | keine Daten | |
| Chairman of Hepatitis B Clinical Advisory Board | no data | keine Daten | keine Daten | |
| Independent Director | 14.1yrs | US$459.60k | 0.037% $ 898.3k | |
| Member of Alpha-1 Antitrypsin Deficiency Clinical Advisory Board | no data | keine Daten | keine Daten | |
| Member of Hepatitis B Clinical Advisory Board | no data | keine Daten | keine Daten | |
| Member of Hepatitis B Clinical Advisory Board | no data | keine Daten | keine Daten | |
| Member of Hepatitis B Clinical Advisory Board | no data | keine Daten | keine Daten |
13.8yrs
Durchschnittliche Betriebszugehörigkeit
65yo
Durchschnittliches Alter
Erfahrener Vorstand: ARWRDie Vorstandsmitglieder sind sehr erfahren ( 13.6 ).